Emmaus Life Sciences(EMMA)

Focus: Emmaus Life Sciences is a public biotech company focused on oral amino acid treatments for rare and metabolic diseases, with a highly concentrated business model centered on a single approved product.

Rare Diseases Metabolic Diseases

Profile data last refreshed 22h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Emmaus Life Sciences

AI assessmentNot Hiring

No open roles listed right now. Follow Emmaus Life Sciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$17M

FY2025

Key Products

ENDARI

Sickle cell disease

$8M Part D

Peak

Sole revenue driver generating 100% of company sales, FDA-approved NDA in peak lifecycle phase.

Help build intelligence for Emmaus Life Sciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Rare disease focus provides meaningful impact in underserved patient populations with sickle cell disease and metabolic disorders
Public company status offers equity upside potential and access to capital markets for growth
Simplified product portfolio in oral amino acid space allows deep expertise development in a specialized niche

Watch Out For

Extreme revenue concentration (100% from ENDARI) creates significant business risk if product faces competition or safety issues
Declining financial trajectory with revenue dropping 43% YoY ($30M to $17M) and only $1M cash remaining signals potential liquidity crisis
Zero active pipeline programs and no clinical trials indicate minimal future growth prospects or new product development
Critically low R&D spending (4% intensity, $657K in FY2025) suggests inability to invest in next-generation therapies

Generated by Claude from Emmaus Life Sciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Secondary product with approaching loss of exclusivity; limited financial contribution evident from revenue concentration data.

L-GLUTAMINE

Acute complications of sickle cell disease

Post-LOE

Post-LOE ANDA product representing competitive generic erosion in core therapeutic area.